MS linked to epigenetic changes in immune cells
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Swiss Biotech Day 2019
/in News/by Thomas GabrielczykThe Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and […]
Confo Therapeutics raise 30m in Series A financing
/in News/by Thomas GabrielczykThe round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
Researchers report how body fat affects imune cells
/in News/by Thomas GabrielczykUS scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets 36.5m support from IMI
/in News/by Thomas GabrielczykThe European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
/in News/by Thomas GabrielczykTransgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgènes armed oncolytic immunotherapies.
Alentis Therapeutics debuts with CHF12.5m
/in News/by Thomas GabrielczykLiver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
EMA recommends nine drugs for market approval
/in News/by Thomas GabrielczykIn its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation.
A novel strategy against rheumatoid arthritis
/in News/by Thomas GabrielczykResearchers at AstraZeneca, Viela Bio, Gilead Sciences, Antidote Therapeutics Inc., and at SoseiHeptares report on a new small molecule compound to treat RA.
US patent office grants Charpentier CRISPR patent
/in News/by Thomas GabrielczykThe US Patent Office has granted the Charpentier/Doudna key CRISPR patent, which was previously involved in an interference proceeding.